VIP and the Neuroimmune Axis: VPAC1/VPAC2 Biology Across Systems | QSC Research
QSC Research · Published 2025-03-10
VIP and the Neuroimmune Axis: VPAC1/VPAC2 Biology Across Systems
Vasoactive intestinal peptide (VIP) is one of the most broadly expressed regulatory neuropeptides in the body — present in the gut, lungs, CNS, immune system, and circadian pacemaker. Its two receptors (VPAC1 and VPAC2) mediate anti-inflammatory effects in immune cells, vasodilation in pulmonary and systemic vasculature, bronchodilation in airways, and phase-resetting in the suprachiasmatic nucleus. This piece covers the multi-system biology of VIP for researchers designing neuroimmune, pulmonary, and circadian studies.
VPAC1 and VPAC2 — Receptor Distribution and Function
Receptor
Primary tissue expression
Primary function
VPAC1
Macrophages, T-cells, gut epithelium, vascular endothelium, liver
VPAC1-selective agonist: [K15, R16, L27]-VIP(1-7)/GRF(8-27) and related hybrids. VPAC2-selective agonist: Ro25-1553 (commercial research compound). VPAC1 antagonist: VIP6-28 (truncated VIP). VPAC2 knockout: well-characterised mouse model for circadian biology. These tools allow dissection of VPAC1 vs VPAC2 contributions to VIP effects.
️
VIP as Neuroimmune Anti-Inflammatory — The SASP Connection
↓cytotoxic activity (anti-inflammatory in autoimmune models)
In arthritis, colitis, and EAE (multiple sclerosis model) preclinical studies, VIP consistently reduces inflammatory severity through these immune cell mechanisms — positioning it as a neuroimmune anti-inflammatory compound with a profile distinct from conventional cytokine inhibitors.
Pulmonary Arterial Hypertension — VIP Deficiency and Vasodilation
Aspect
Detail
VIP in PAH lung
VIP significantly deficient in lung tissue of PAH patients vs controls — Hamidi et al. 2008
Inhaled VIP reduced mean PAP and PVR in 8 PAH patients — proof-of-concept for VPAC-mediated pulmonary vasodilation
Mechanistic distinction
PDE5i (sildenafil): prevents cGMP breakdown. Bosentan: ET-1 receptor antagonism. VIP: direct VPAC1/2 → cAMP → vasodilation. Three non-overlapping pathways.
VIP for PAH research model
Monocrotaline (MCT) rat model is the standard VIP pulmonary hypertension research model. MCT 60 mg/kg SC establishes PAH within 21-28 days. VIP administered via IV infusion or inhalation. Endpoints: RVSP (invasive), Fulton index (RV hypertrophy), pulmonary vascular morphometry (media thickness/adventitia), eNOS/iNOS expression, plasma cAMP.
Circadian Biology — VPAC2/SCN Connection
VIP in the circadian pacemaker:
Finding
Implication
VPAC2 knockout mice (Aton 2005, Nat Neurosci)
Loss of circadian rhythmicity in SCN — established VPAC2 as essential for pacemaker synchronisation
VIP neurons in SCN
VIP-expressing SCN neurons are the primary coupling signal between SCN oscillator cells
Phase shifting
VIP applied to SCN slices at CT6 vs CT12 produces opposite phase shifts — captures circadian gating
Circadian disruption research
VPAC2 antagonism (or KO) is the model for studying pacemaker decoupling — relevant to shift work, jet lag, and ageing-related circadian disruption
SCN explant PER2::LUC protocol
For circadian research: SCN slices from PER2::LUC reporter mice. VIP 1 µM applied at defined circadian times (CT6 = subjective day, CT12 = subjective dusk onset). Record bioluminescence for 5-7 days post-application. Phase shift magnitude and direction — maps the circadian response curve (CRC) for VIP.
❓
Frequently Asked Questions
What is VIP (vasoactive intestinal peptide)?
VIP is a 28 amino acid neuropeptide with broad tissue distribution — gut, lungs, immune system, CNS. It activates VPAC1 (anti-inflammatory, vascular) and VPAC2 (circadian SCN, airway) — both Gs-coupled class B GPCRs driving cAMP signalling.
Why is VIP deficient in pulmonary arterial hypertension?
The mechanism is not fully established. Current evidence suggests VIP production in pulmonary endothelium is reduced under PAH pathology — potentially contributing to the vasoconstriction and vascular remodelling that characterises PAH. VIP deficiency creates a pro-vasoconstrictive state that VIP replacement can partially reverse.
What makes VIP unique as a research compound vs conventional anti-inflammatory drugs?
VIP has a neuroimmune origin — it is produced by neurons innervating immune organs and acts on immune cells to modulate their response. This makes VIP the primary research tool for studying the neurological control of immune function (neuroimmunology). Conventional anti-inflammatory drugs (NSAIDs, corticosteroids, cytokine inhibitors) do not target the neural-immune interface that VIP engages.
